DGRh-Empfehlungen zur Implementierung aktueller Sicherheitsaspekte in die NSAR- Therapie muskuloskelettaler Schmerzen

W. Bolten,K. Krüger,S. Reiter-Niesert,D. Stichtenoth
Abstract:NSAIDs exert their anti-inflammatory and analgesic effects by inhibition of COX-2, a key enzyme for proinflammatory prostanoid synthesis. Therapy with NSAIDs is limited by their typical gastrointestinal, cardiovascular and renal side effects, which are caused by inhibition of COX-1 (gastrointestinal toxicity), COX-2 (cardiovascular side effects) or both COX-isoenzymes (renal side effects). Appropriate prevention strategies should be employed in patients at risk. If gastrointestinal risk factors are present, co-administration of a proton pump inhibitor or misoprostol is recommended; in patients with cardiovascular risk, coxibs, diclofenac and high-dose ibuprofen should be avoided. Furthermore, drug interactions and contraindications should be considered. In patients with renal impairment (GFR < 30 ml/min) all NSAIDs must be avoided. Ulcer anamnesis is a contraindication for traditional NSAIDs. Preexisting cardioor cerebrovascular diseases are contraindications for coxibs. Treatment decisions should be individually based with a continuous monitoring of the risk – benefit ratio and exploitation of nonpharmacological treatment options.
What problem does this paper attempt to address?